Effectiveness of probiotics on COVID-19 prevention and treatment against mild COVID-19 in outpatient care: A systematic review.

IF 1.4 Q3 NUTRITION & DIETETICS
Chung Hang Hannah Chau, Denes Stefler, Michelle Man Sum Szeto
{"title":"Effectiveness of probiotics on COVID-19 prevention and treatment against mild COVID-19 in outpatient care: A systematic review.","authors":"Chung Hang Hannah Chau, Denes Stefler, Michelle Man Sum Szeto","doi":"10.1177/02601060251378200","DOIUrl":null,"url":null,"abstract":"<p><p>BackgroundIn previous research, probiotics have shown to be beneficial in preventing and limiting the progress of upper respiratory infections. Their effectiveness in relation to coronavirus disease 2019 (COVID-19) has been investigated mainly in hospitalized patients, and less so among outpatients who constitute majority of COVID-19 cases.AimThis systematic review evaluates the available evidence regarding the effectiveness of probiotic use on prevention and treatment of COVID-19 among patients with mild symptoms in outpatient settings.MethodsPubMed, Embase and Cochrane Library were searched for studies from their inception to May 2024, restricting to randomized controlled trials and before-and-after studies. The primary outcomes were infection incidence and complete remission rate. Cochrane risk-of-bias tool (RoB 2.0) and risk of bias in non-randomized studies of interventions tool (ROBINS-I) were used to assess the risk of bias. The Grading of Recommendations, Assessment, Development, and Evaluations approach was performed to assess the certainty of the evidence.ResultsEight randomized controlled trials and one pre-post study on 1235 participants were included. Four studies had low risk of bias. Probiotics were effective in reducing the incidence of COVID-19 upon exposure and accelerating the symptomatic remission of mild COVID-19 with less systemic symptoms. Overall, the certainty of evidence on both primary outcomes was moderate. Comorbidities and old ages were found to be significant confounders. Probiotics demonstrated significant immunomodulatory and humoral effects in the nasopharyngeal cavity.ConclusionThese results suggest that probiotics are effective at preventing COVID-19 and support faster recovery from mild COVID-19 among individuals seeking for outpatient care. People with comorbidities, that is, metabolic disorder and elderly benefit the most from probiotics supplements.</p>","PeriodicalId":19352,"journal":{"name":"Nutrition and health","volume":" ","pages":"2601060251378200"},"PeriodicalIF":1.4000,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nutrition and health","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/02601060251378200","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"NUTRITION & DIETETICS","Score":null,"Total":0}
引用次数: 0

Abstract

BackgroundIn previous research, probiotics have shown to be beneficial in preventing and limiting the progress of upper respiratory infections. Their effectiveness in relation to coronavirus disease 2019 (COVID-19) has been investigated mainly in hospitalized patients, and less so among outpatients who constitute majority of COVID-19 cases.AimThis systematic review evaluates the available evidence regarding the effectiveness of probiotic use on prevention and treatment of COVID-19 among patients with mild symptoms in outpatient settings.MethodsPubMed, Embase and Cochrane Library were searched for studies from their inception to May 2024, restricting to randomized controlled trials and before-and-after studies. The primary outcomes were infection incidence and complete remission rate. Cochrane risk-of-bias tool (RoB 2.0) and risk of bias in non-randomized studies of interventions tool (ROBINS-I) were used to assess the risk of bias. The Grading of Recommendations, Assessment, Development, and Evaluations approach was performed to assess the certainty of the evidence.ResultsEight randomized controlled trials and one pre-post study on 1235 participants were included. Four studies had low risk of bias. Probiotics were effective in reducing the incidence of COVID-19 upon exposure and accelerating the symptomatic remission of mild COVID-19 with less systemic symptoms. Overall, the certainty of evidence on both primary outcomes was moderate. Comorbidities and old ages were found to be significant confounders. Probiotics demonstrated significant immunomodulatory and humoral effects in the nasopharyngeal cavity.ConclusionThese results suggest that probiotics are effective at preventing COVID-19 and support faster recovery from mild COVID-19 among individuals seeking for outpatient care. People with comorbidities, that is, metabolic disorder and elderly benefit the most from probiotics supplements.

益生菌在门诊预防和治疗轻症COVID-19中的效果:系统评价。
在之前的研究中,益生菌已被证明对预防和限制上呼吸道感染的进展有益。它们与2019冠状病毒病(COVID-19)相关的有效性主要在住院患者中进行调查,而在占COVID-19病例大多数的门诊患者中进行的调查较少。目的本系统综述评估了门诊使用益生菌预防和治疗轻症患者COVID-19有效性的现有证据。方法检索spubmed、Embase和Cochrane图书馆自建立之初至2024年5月的研究,限于随机对照试验和前后对照研究。主要结局是感染发生率和完全缓解率。采用Cochrane风险偏倚工具(RoB 2.0)和非随机干预研究的偏倚风险工具(ROBINS-I)评估偏倚风险。采用推荐、评估、发展和评估的分级方法来评估证据的确定性。结果共纳入8项随机对照试验和1项前后研究,共1235名受试者。4项研究的偏倚风险较低。益生菌可有效降低暴露后COVID-19的发病率,并加速轻度COVID-19的症状缓解,但全身性症状较少。总的来说,这两个主要结局的证据的确定性是中等的。合并症和年龄是重要的混杂因素。益生菌在鼻咽腔中具有显著的免疫调节和体液调节作用。结论益生菌可有效预防COVID-19,并支持寻求门诊治疗的轻度COVID-19患者更快康复。有合并症的人,即代谢紊乱的人和老年人从益生菌补充剂中获益最多。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Nutrition and health
Nutrition and health Medicine-Medicine (miscellaneous)
CiteScore
3.50
自引率
0.00%
发文量
160
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信